IC50 of CTL and SorR cells towards sorafenib treatment.
收藏数据链接：
官方服务：
资源简介：
IC50 of CTL and SorR cells towards sorafenib treatment.
应用场景：
创建时间：
2015-12-02
相关数据集
An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer
Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm
NIAID Data Ecosystem80
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main
NIAID Data Ecosystem40
Tumor number and volume of offspring at sacrifice (22 weeks).
Data expressed as Mean��SEM and differences between treatment groups were determined by one way ANOVA and appropriate post hoc test. Differences with a p*. n = number of mice/group, tumor volume expre
Figshare2015-12-02 更新10
Cytotoxicity of Ruthenium–Arene Complexes Containing β‑Ketoamine Ligands
New ruthenium(II) arene derivatives (arene = p-cymene, benzene, hexamethylbenzene) containing β-ketoamine ligands L′ (HL′ in general; in detail, HLph,ph = (4Z)-3-methyl-4-((phenylamino)(phenyl)meth
NIAID Data Ecosystem50
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
NIAID Data Ecosystem20
